COMMUNIQUÉS West-GlobeNewswire

TRACON Pharmaceuticals to Present at 30th Annual ROTH Conference
06/03/2018
SAN DIEGO, March 06, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON ), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer [...]
Zafgen Reports Fourth Quarter and Full Year 2017 Financial Results; Announces Positive Interim Data from Ongoing ZGN-1061 Phase 2 Proof-of-Concept Trial in Patients with Type 2 Diabetes
06/03/2018
ZGN-1061 interim data suggest compound is safe and well-tolerated; no safety signals and placebo-like side effect profile ZGN-1061 interim efficacy data indicate significant A1C lowering vs. placebo at 8 weeks ZGN-1258 [...]
Portola Pharmaceuticals to Present at Two Upcoming Investor Conferences
06/03/2018
SOUTH SAN FRANCISCO, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA ) today announced that Bill Lis, chief executive officer, will present at the following conferences in March [...]
Atara Biotherapeutics to Present at the Cowen and Company 38th Annual Health Care Conference
06/03/2018
SOUTH SAN FRANCISCO, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA ), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, [...]
National Coordination Center to Support VA EMR with Resources from Top U.S. Health Care Organizations
06/03/2018
WASHINGTON, March 06, 2018 (GLOBE NEWSWIRE) -- The founding members of the National Coordination Center's Department of Veterans Affairs (VA) Steering Committee today announced their commitment to help support the VA’s [...]
Clearside Announces Proposed Public Offering of Common Stock
06/03/2018
ALPHARETTA, Ga., March 06, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ: CLSD ), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases [...]
Editas Medicine Announces Fourth Quarter and Full Year 2017 Results and Update
06/03/2018
EDIT-101 for Leber Congenital Amaurosis type 10 (LCA10) on track for mid-2018 Investigational New Drug (IND) filing Expecting at least five clinical-stage programs by end of 2022 as part of EM22 five-year goals Year-end [...]
Nuvectra™ Reports Fourth Quarter and Full Year 2017 Financial Results
06/03/2018
PLANO, Texas, March 06, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR ), a neurostimulation medical device company, today announced financial results for the fourth quarter and full year ended December 31 [...]
Optinose to Report Fourth Quarter and Full Year 2017 Financial Results and Corporate Updates on March 13, 2018
06/03/2018
YARDLEY, Pa., March 06, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ: OPTN ), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will [...]
Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial Results
06/03/2018
ZX008 Granted Breakthrough Therapy Designation in Dravet syndrome by FDA Last patient randomized into second Phase 3 clinical trial of ZX008 in patients with Dravet syndrome, Study 1504 Initiated global Phase 3 clinical [...]
Adverum Biotechnologies Reports Fourth Quarter 2017 Financial Results and Provides Corporate Update
06/03/2018
MENLO PARK, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM ), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, today [...]
Align Technology to Host Investor Day on May 23, 2018
06/03/2018
SAN JOSE, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Align Technology, Inc. (NASDAQ: ALGN ) today announced that it will host an Investor Day on Wednesday, May 23, 2018, at the Park Central Hotel in New York City. [...]
T2 Biosystems Reports Fourth Quarter and Full-Year 2017 Financial Results and Business Update
06/03/2018
LEXINGTON, Mass., March 06, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO ), an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in [...]
Media Advisory: Theratechnologies to Hold a Conference Call Today
06/03/2018
MONTREAL, March 06, 2018 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ( Theratechnologies ) (TSX: TH ) and its partner TaiMed Biologics, Inc. (TaiMed) today announced that the U.S. Food and Drug Administration (FDA) has [...]
Avis aux médias : Theratechnologies tiendra un appel conférence aujourd’hui
06/03/2018
MONTRÉAL, 06 mars 2018 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH ) et son partenaire TaiMed Biologics, Inc. (TaiMed) ont annoncé aujourd’hui que la Food and Drug Administration (FDA) aux [...]
Anthera Pharmaceuticals Deemed Compliant with Nasdaq Listing Criteria
06/03/2018
HAYWARD, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals (Nasdaq: ANTH ) today announced that Anthera has received formal notice from The NASDAQ Stock Market LLC (“Nasdaq”) indicating that the Company [...]
GIAPREZA™ (angiotensin II) Significantly Improved Survival and Reduced Time on Renal Replacement Therapy in Patients with Acute Kidney Injury
06/03/2018
Analyses to Be Presented in Oral and Poster Sessions at The 23rd International Conference on Advances in Critical Care Nephrology AKI & CRRT 2018 Manuscript Published Online in Critical Care Medicine SAN DIEGO, [...]
Adamas to Present at Two Upcoming Investor Conferences
06/03/2018
EMERYVILLE, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS ) today announced that company management is scheduled to present at two upcoming investor conferences: Gregory T. Went, [...]
Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzo™ (ibalizumab-uiyk) Injection, the First HIV-1 Inhibitor and Long-Acting Monoclonal Antibody for Multidrug Resistant HIV-1
06/03/2018
First HIV treatment approved with a new mechanism of action in more than 10 years Infused every two weeks, only antiretroviral treatment (ART) that does not require daily dosing Trogarzo™ has no drug-drug interactions [...]

Pages